Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.
暂无分享,去创建一个
A. Ravaud | T. Choueiri | M. Atkins | M. Michaelson | P. Tomczak | G. Gravis | Benjamin Wu | L. Navale | K. Drosik | Shirley S. Wong | T. Demkow | D. Warner